Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office	Docket No. CARP-0124	Application No. 10/581,856
	Applicant Vicente R. Tur et al.	
	Filing Date December 6, 2004	Group Not Yet Assigned
	Confirmation No. 4628	

FOREIGN PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Country	Translation YES	Translation NO
/DG/	1	88/06625	09/07/88	WO		
/DG/	2	99/36535	07/22/99	WO		
/DG/	3	01/00832	01/04/01	WO		
/DG/	4	03/29420	04/10/03	WO		
/DG/	5	04/01009	12/31/03	WO		

EXAMINER /Daniel Gamett/ (08/24/2009)	**DATE CONSIDERED**

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DG/

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office	Docket No. CARP-0124	Application No. 10/581,856
	Applicant Vicente R. Tur et al.	
	Filing Date December 6, 2004	Group Not Yet Assigned
	Confirmation No. 4628	

NON-PATENT DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
	6	Cha, SS et al., "2.8 Å Resolution Crystal Structure of Human TRAIL, a Cytokine with Selective Antitumor Activity," *Immunity*, **1999**, *11(2)*, 253-261
	7	Degli-Esposti et al., "Cloning and Characterization of TRAIL-R3, a Novel Member of the Emerging TRAIL Receptor Family," *J. Exp. Med.*, **1997**, *186(7)*, 1165-1170
	8	Eck, MJ et al., "The Structure of Human Lymphotoxin (Tumor Necrosis Factor-β) at 1.9-Å Resolution," *J. Biol. Chem.*, **1992**, *267(4)*, 2119-2122
	9	Filikov et al., "Computational stabilization of human growth hormone," *Protein Sci.*, **2002**, *11*, 1452-1461
	10	Hymowitz, S.G. et al., "A Unique Zinc-Binding Site Revealed by a High-Resolution X-ray Structure of Homotrimeric Apo2L/TRAIL," *Biochemistry*, **2000**, *39(4)*, 633-640
	11	Hymowitz, SG et al., "Triggering Cell Death: The Crystal Structure of Apo2L/TRAIL in a Complex with Death Receptor 5," *Mol. Cell.*, **1999**, *4(4)*, 563-571
	12	Kelley, R.F. et al., "Receptor-selective mutants of Apo2L/TRAIL reveal a greater contribution of DR5 and DR4 to apoptosis signaling," e-published ahead of print November 1, **2004**, Manuscript #M410660200v1, 1-41
	13	Luo et al., "Development of a cytokine analog with enhanced stability using computational ultrahigh throughput screening," *Protein Sci.*, **2002**, *11*, 1218-1226
	14	Mongkolsapaya, J. et al., "Structure of the TRAIL-DR5 complex reveals mechanisms conferring specificity in apoptotic initiation," *Nat. Struct. Biol.*, **1999**, *6(11)*, 1048-1053
	15	Screaton et al., "TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL," *Curr. Biol.*, **1997**, *7(9)*, 693-696
	16	Shanafelt, A.B. et al., "An immune cell-selective interleukin 4 agonist," *PNAS*, **1998**, *95(16)*, 9454-9458
	17	Van der Sloot, A. et al., "Stabilization of TRAIL, an all-β-sheet multimeric protein, using computational redesign," *Protein Engineering, Design & Selection*, **2004**, *17(9)*, 673-680

EXAMINER	/Daniel Gamett/ (09/03/2009)	**DATE CONSIDERED**

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DG/